Windward Bio secured $165 million to fund clinical trials of long-acting antibody programs in respiratory diseases and related indications. The financing supports a lead program in asthma and COPD and a second program intended for additional uses in respiratory and dermatological settings, with both described as long-acting antibodies designed to offer dosing advantages. The round stands out as a signal of continued appetite for immunology-focused development, particularly when dosing frequency and adherence are positioned as differentiators.